GSK (NYSE:GSK) Share Price Crosses Above 200 Day Moving Average – Here’s What Happened

GSK PLC Sponsored ADR (NYSE:GSK) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $43.39 and traded as high as $50.50. GSK shares last traded at $49.11, with a volume of 6,545,191 shares trading hands.

Wall Street Analyst Weigh In

GSK has been the topic of several recent analyst reports. Bank of America raised shares of GSK from an “underperform” rating to a “neutral” rating in a research note on Tuesday, November 25th. HSBC reaffirmed a “reduce” rating on shares of GSK in a research report on Wednesday, December 10th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday. Weiss Ratings reissued a “buy (b)” rating on shares of GSK in a research note on Monday, December 29th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a research report on Monday, October 27th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $44.13.

GSK Trading Down 3.3%

The stock has a market capitalization of $100.11 billion, a P/E ratio of 13.87, a P/E/G ratio of 1.27 and a beta of 0.45. The stock’s 50 day moving average price is $48.54 and its 200-day moving average price is $43.39. The company has a quick ratio of 0.55, a current ratio of 0.84 and a debt-to-equity ratio of 0.95.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 29th. The pharmaceutical company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.22. The company had revenue of $11.35 billion during the quarter, compared to the consensus estimate of $8.21 billion. GSK had a net margin of 17.16% and a return on equity of 48.64%. GSK’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 earnings per share. GSK has set its FY 2025 guidance at 4.730-4.810 EPS. As a group, equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 8th. Investors of record on Friday, November 14th were paid a dividend of $0.4171 per share. This represents a $1.67 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date was Friday, November 14th. GSK’s dividend payout ratio is 48.02%.

Insider Transactions at GSK

In related news, major shareholder Plc Gsk bought 1,470,000 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were bought at an average price of $19.00 per share, for a total transaction of $27,930,000.00. Following the completion of the purchase, the insider directly owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. This trade represents a 8.76% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is owned by company insiders.

Institutional Trading of GSK

Hedge funds have recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of GSK during the 2nd quarter valued at $25,000. CNB Bank acquired a new position in GSK during the 3rd quarter valued at about $31,000. SOA Wealth Advisors LLC. raised its stake in GSK by 252.1% in the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 605 shares during the last quarter. CoreFirst Bank & Trust purchased a new stake in GSK in the second quarter valued at about $33,000. Finally, MTM Investment Management LLC acquired a new stake in GSK in the second quarter worth about $37,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.